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Available online 09 November 2016Background: PCSK9 inhibition with alirocumab signiﬁcantly reduced LDL-C levels in trials of up to 78 weeks'
duration in patients with heterozygous familial hypercholesterolemia (HeFH). We report results from 3 years
of an ongoing open-label treatment extension (NCT01576484) to a 12-week double-blind trial in HeFH patients
(NCT01266876).
Methods: Patients who completed the parent study and were receiving stable daily statin ± ezetimibe could
enter the open-label extension, where they received alirocumab 150 mg every 2 weeks (Q2W) subcutaneously
(n= 58). The primary endpoint was safety (treatment-emergent adverse events, TEAEs). Efﬁcacy endpoints in-
cluded the percentage change in LDL-C from baseline at Week 24. Safety and efﬁcacy data were available up to
Weeks 156 and 148, respectively.
Results: Mean baseline LDL-C was 150.7 mg/dL (3.9 mmol/L), despite all patients being on a statin (76% on
high-intensity statin; 72% also receiving ezetimibe). Over 156 weeks, 54 (93.1%) patients experienced a TEAE,
12 (20.7%) experienced a serious TEAE, and two (3.4%) discontinued due to a TEAE. Injection site reactions oc-
curred in 21 (36.2%) patients. Mean (SD) reduction in LDL-C from baseline to Week 24 was 65.4 (21.1)%, with
reductionsmaintained through 148weeks (Week 148 reduction: 56.0 [23.8]%).Mean apolipoprotein B reduction
was 50.9% andmedian lipoprotein (a) reductionwas 22.5% atWeek24 (46.1% and 25.6% atWeek148, respective-
ly).
Conclusions: Open-label treatment for 3 years with alirocumab 150 mg Q2W, administered with background
statin± ezetimibe,was generallywell-tolerated and had a safety proﬁle comparablewith that seen in the overall
alirocumab clinical trial program. Alirocumab provided signiﬁcant, sustained LDL-C reductions.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Heterozygous familial hypercholesterolemia (HeFH) is one of the
most common genetic disorders, with an estimated prevalence of one
in every 200 to 500 individuals [1,2]. HeFH is associated with elevated
levels of low-density lipoprotein cholesterol (LDL-C) and increased
life-long risk of premature cardiovascular disease (CVD) [1,2]. HeFH is
usually diagnosed clinically on the basis of lipid proﬁle, physical
ﬁndings, and family history, although genetic testing may also be
performed, with mutations in genes for LDLR, APOB and PCSK9 being
associated with the FH phenotype [1–3].
Current recommended treatment for HeFH is high-dose statin ther-
apy in combination with other lipid-lowering therapies (LLTs) such as
ezetimibe [1–3]. European guidelines recommend LDL-C goals ofe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
755R. Dufour et al. / International Journal of Cardiology 228 (2017) 754–760b1.8 mmol/L (70 mg/dL) for patients with HeFH who have established
coronary heart disease (CHD), and b2.6 mmol/L (100 mg/dL) in those
without CHD [4]. The National Lipid Association recommends LDL-
C b 100 mg/dL or ≤50% reduction [3]. However, it is recognized that,
due to their high baseline LDL-C, many patients with HeFH will not
reach these goals even with the currently available maximally tolerated
statin therapy and other LLTs such as ezetimibe [1,2,5,6].
Inhibition of proprotein convertase subtilisin/kexin type 9
(PCSK9) with alirocumab, a fully human monoclonal antibody, sig-
niﬁcantly reduced LDL-C and other atherogenic lipids in patients
with HeFH in trials with double-blind periods of up to 78 weeks [7,
8]. In Phase 3 trials including patients with HeFH not at LDL-C goal
on study entry, most patients (N70%) achieved risk-based LDL-C
goals of b70 or b100mg/dL with alirocumab added tomaximally tol-
erated statin and other LLTs [7]. Frequencies of treatment-emergent
adverse events (TEAEs) with alirocumab treatment were generally
similar to those observed with placebo controls in the trials [7,8].
However, due to the chronic nature of HeFH, studies of even longer
duration are required to evaluate the efﬁcacy and safety of this new
drug.
We report here safety and efﬁcacy results from over 3 years of open-
label treatment with alirocumab in patients with HeFH. These results
are from an ongoing open-label extension study (NCT01576484) of a
previous double-blind 12-week study [8].
2. Methods
2.1. Overview of parent study
Methods for the parent study have been described previously [8]. Brieﬂy, the study
was conducted in the USA and Canada and included men and women with a clinical
diagnosis of HeFH (≥8 points on the World Health Organization criteria) who were
receiving stable statin dose (with or without ezetimibe) and who had LDL-C ofFig. 1. Patient disposition. AE, adverse event, HeFH, heterozygous familial hypercholes≥100 mg/dL (2.6 mmol/L) at screening. Patients were randomized to 12 weeks of
double-blind treatmentwith placebo or one of four alirocumab doses (Fig. 1). Alirocumab
and placebowere administered subcutaneously. Of 77 patients randomized, 76 completed
the parent study.
2.2. Open-label extension
All patients who successfully completed the parent study were eligible for the open-
label extension study if they provided signed, informed consent. Patients had to be on a
stable daily statin regimen for at least 3weeks prior to screening. Other LLTswere allowed
provided that they were also on a stable regimen for at least 3 weeks (6 weeks for
fenoﬁbrate; other ﬁbrates were not allowed). Exclusion criteria were as for the parent
study [8].
In this extension study, all patients received open-label alirocumab 150 mg every 2
weeks (Q2W), administered subcutaneously as a 1-mL injection. Patients or their care-
givers received training to administer injections at home. Adjustment of dose from
150 mg was not allowed according to the protocol, although investigators were allowed
to skip doses in the case of two consecutive LDL-C values b25 mg/dL (0.65 mmol/L),
e.g., the drug could be given every 4 weeks (Q4W) instead of Q2W. It was also possible
for the investigator to adjust the patient's background lipid-lowering medication to
optimize LDL-C levels. The open-label study was planned to remain open until product
approval, or up to 4 years, or until the program was halted. The study protocol was ap-
proved by the appropriate Independent Review Board/Ethics Committee. All investigators
conducted the study in accordance with ethical guidelines based on the Declaration of
Helsinki, and with the ICH guidelines for Good Clinical Practice and applicable
regulatory requirements.
2.3. Endpoints
The primary aim of the trial was to assess the long-term safety and tolerability of
alirocumab in patients with HeFH. Secondary aims included the long-term assessment
of alirocumab efﬁcacy in reducing LDL-C, and effects on other lipid parameters.
The pre-speciﬁed primary endpoint was the assessment of TEAEs in the open-label
extension from baseline up to the last dose of study drug +10 weeks. Safety data are re-
ported for all patients for the duration of their treatment. CV events were adjudicated.
As well as standard Medical Dictionary of Regulatory Activities (MedDRA) preferred
terms, TEAEs were also assessed in categories of special interest (i.e., those potentially rel-
evant to the new drug class or mode of administration), including injection site reactions,
general allergic events, neurological events, and neurocognitive disorders. The categoriesterolemia, OLT, open-label treatment, Q2W, every 2 weeks, Q4W, every 4 weeks.
Table 1
Baseline characteristics and lipid parameters of patients entering the open-label treatment
extension⁎.
Alirocumab 150 mg Q2W (n = 58)
Age, years, mean (SD) 54.4 (9.4)
Gender, male, n (%) 38 (65.5)
Race, White, n (%) 55 (94.8)
Body mass index, kg/m2, mean (SD) 29.3 (4.1)
History of CAD, n (%) 27 (46.6)
Diabetes mellitus, n (%) 3 (5.2)
Statin therapy, n (%) 58 (100)
High-intensity statin† 44 (75.9)
Ezetimibe use, n (%) 42 (72.4)
Baseline lipid parameters, mean (SD)
Calculated LDL-C, mg/dL [mmol/L] 150.7 (40.4) [3.9 (1.0)]
Apo B, mg/dL 121.4 (24.0)
Non-HDL-C, mg/dL [mmol/L] 175.8 (42.6) [4.6 (1.1)]
Total cholesterol, mg/dL [mmol/L] 227.8 (45.6) [5.9 (1.2)]
Lipoprotein(a), mg/dL 40.0 (5.0: 104.0)‡
Triglycerides, mg/dL [mmol/L] 113.0 (87.0: 160.0) [1.3 (1.0: 1.8)]‡
HDL-C, mg/dL [mmol/L] 51.9 (15.3) [1.3 (0.4)]
Apo A1, mg/dL 147.7 (24.0)
Apo, apolipoprotein; CAD, coronary artery disease; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol.
⁎ Baseline values deﬁned as the last available value collected in the current study before
the ﬁrst dose of the open-label treatment.
† Deﬁned as atorvastatin 40–80 mg daily, rosuvastatin 20–40 mg daily, or simvastatin
80 mg daily.
‡ Median (Q1:Q3).
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Phase 3 ODYSSEY trials [7,9].
Pre-speciﬁed efﬁcacy endpoints included the percent change in LDL-C, apolipoprotein
(apo) B, non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, HDL-C,
apo A1, lipoprotein (a) (Lp[a]), and triglycerides from baseline to Week 24, and the pro-
portion of patients reaching LDL-C goals at Week 24 of b70 mg/dL (1.8 mmol/L) in case
of prior myocardial infarction (MI)/stroke, or b100 mg/dL (2.6 mmol/L) without prior
MI/stroke. Percent changes in lipids from baseline to the latest time point with available
data are also reported. Blood samples for lipid analysis were obtained at baseline and
weeks 2, 4, 8, 12, 16, and 24, and subsequently at approximately 12-week intervals. Labo-
ratory analysis methods have been previously described [7,8].
For patientswith LDL-C levels b25mg/dL (0.65mmol/L) at two consecutive laboratory
assessments during the study, the investigator reviewed the patient data and decided
whether to continue, discontinue or temporary discontinue study treatment.
Anti-drug antibodies (ADAs) to alirocumab were assessed at regular intervals using a
validated immunoassay by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). A pos-
itive ADA response was described as “persistent” if it was detected on consecutive sam-
ples. The ADA assay incorporated false-positive rates recommended by published
guidelines as reported previously [7].
2.4. Statistical analysis
Safety data were analyzed by descriptive statistics. As safety was the primary end-
point, formal statistical analysis of efﬁcacy variables was not planned. However, a post
hoc analysis of efﬁcacy data was conducted, comparing the LDL-C value at each time
point to baseline using a one-sample t-test.
3. Results
3.1. Patients
Ninemonths separated the end of the parent study and the start of the
open-label extension. During this 9-month period, patients were not re-
ceiving alirocumab. In total, 58 patients (75% of those who completed
the parent study) entered the extension study; of these, 51 (87.9%) re-
ceived open-label treatment for up to 156weeks (3 years). Seven patients
(12.1%) discontinued before Week 156 and a further one patient
discontinued after Week 156, for a total of eight patients (13.8%) who
discontinued (Fig. 1). Of patients who discontinued, one patient
discontinueddue to anAEof epigastric discomfort after 28weeks of expo-
sure to alirocumab (this AE was not considered related to study treat-
ment); three patients decided not to continue the study (withdrew
consent); one patient was lost to follow-up; two patients had poor com-
pliance to study protocol; and one patient discontinued due to a serious
TEAE (behavioral and psychiatric symptoms of dementia, not considered
related to study treatment) after 180 weeks. Safety data are reported up
to Week 156, as this was the latest time point with data available for all
continuing patients. The latest efﬁcacy assessment completed by all pa-
tients continuing to receive treatment was at Week 148.
The mean baseline LDL-C level was 150.7 mg/dL (3.9 mmol/L),
despite all patients being on a statin, 76% of whom were receiving a
high-intensity statin (atorvastatin 40 to 80 mg daily, rosuvastatin 20
to 40 mg daily, or simvastatin 80 mg daily); furthermore, 72% were
also receiving ezetimibe (Table 1).
3.2. Safety
Following 156 weeks of open-label treatment with alirocumab,
54 (93.1%) of patients experienced a TEAE, 12 (20.7%) experienced a
serious TEAE, and two patients (3.4%) discontinued due to a TEAE
(Table 2). Therewere nodeaths. Twopatients (3.4%) had an adjudicated
cardiovascular event (both coronary revascularization procedures;
Table 2).
With regards to TEAEs of special interest, TEAEs categorized
as injection site reactions occurred in 21 (36.2%) of patients
(Table 2). The majority of injection site reactions were of mild
severity and none led to study treatment discontinuation. TEAEs
categorized as allergic events occurred in six (10.3%) patients,
none of which were considered related to alirocumab. Five (8.6%)
patients reported TEAEs categorized as neurologic disorders (Table 2).Three patients (5.2%) reported TEAEs related to neurocognitive
disorders (Table 2). None of the neurological or neurocognitive TEAEs
were considered by the Investigator to be related to alirocumab treat-
ment. One patient discontinued the study following a neurocognitive
TEAE (amnesia). Further details on these TEAEs are shown in the online
Supplemental Table.
There were few instances of elevated levels of creatine kinase or
hepatic transaminases (Table 3). There were no meaningful changes
in mean levels of either glycated hemoglobin (HbA1C) or glucose from
baseline to Week 148 (Table 3). Some patients reported increases in
glucose levels during the study (Table 3); however, these changes
were transitory.
Fourteen patients (24.1%) had two consecutive LDL-C values
b25 mg/dL (0.65 mmol/L) during treatment with alirocumab 150 mg
Q2W. Furthermore,ﬁve patients (8.6%) had two consecutive LDL-C values
b15 mg/dL (0.39 mmol/L). For six of the 14 patients with LDL-
C b 25 mg/dL, the investigator decided to temporarily stop alirocumab
treatment as a safety precaution. One (7.1%) of the 14 patients with two
consecutive LDL-C values b25 mg/dL withdrew from the study (patient
withdrew consent). None of the ﬁve patients with consecutive LDL-
C b 15 mg/dL had their dose changed and all continued treatment (due
to no safety concern in the judgment of the investigator). Neurological
TEAEs occurred in three patients whose LDL-C levels were b25mg/dL be-
fore the event, and in two patients who did not have LDL-C b 25 mg/dL.
Neurocognitive TEAEs occurred in one patient who previously had LDL-
C b 25 mg/dL, and in two patients who did not have LDL-C b 25 mg/dL.
Immunogenicity was examined over the entire course of the
treatment period using highly sensitive assays that generated the
recommended false positive rate to ensure any ADA response was
detected. The incidence of treatment-emergent ADAs was low and the
vast majority (94.8%) of patients did not exhibit any ADA response.
Three patients exhibited positive responses in the ADA assay that
were either persistent, positive for neutralizing antibodies (i.e. ADA
with potential to inhibit binding of alirocumab to PCSK9), or only
positive at the last time point analyzed. A persistent ADAassay response
was reported in one patient who had a low-level pre-existing reactivity
in the ADA assay, with a low titer ADA assay response maintained
through the study (to Week 172). One patient had a transient, low-
titer assay response at a single timepoint (Week 12)whichwas positive
Table 2
Safety: TEAEs during open-label treatment with alirocumab 150 mg Q2W⁎.
All patients
(n = 58)
Patients with any TEAE 54 (93.1)
Patients with any serious TEAE 12 (20.7)
Patients with TEAEs leading to permanent
treatment discontinuation
2 (3.4)
Patients with any TEAE leading to death 0
Adjudicated CV events 2 (3.4)
TEAEs occurring in ≥5% of patients†
System organ class‡ Preferred term‡
Infections and infestations Upper respiratory
tract infection
14 (24.1)
Nasopharyngitis 12 (20.7)
Bronchitis 11 (19.0)
Urinary tract infection 7 (12.1)
Inﬂuenza 6 (10.3)
Gastroenteritis 6 (10.3)
Sinusitis 5 (8.6)
Conjunctivitis 3 (5.2)
Tooth infection 3 (5.2)
Ear infection 3 (5.2)
Blood and lymphatic system
disorders
Anemia 3 (5.2)
Immune system disorders Seasonal allergy 3 (5.2)
Psychiatric disorders Anxiety 5 (8.6)
Nervous system disorders Headache 11 (19.0)
Dizziness 5 (8.6)
Carpal tunnel syndrome 3 (5.2)
Vascular disorders Hypertension 4 (6.9)
Respiratory, thoracic,
and mediastinal disorders
Cough 6 (10.3)
Oropharyngeal pain 3 (5.2)
Gastrointestinal disorders Diarrhea 8 (13.8)
Gastroesophageal
reﬂux disease
4 (6.9)
Nausea 4 (6.9)
Vomiting 4 (6.9)
Abdominal pain 3 (5.2)
Skin and subcutaneous
tissue disorders
Urticaria 4 (6.9)
Musculoskeletal and
connective tissue
disorders
Arthralgia 11 (19.0)
Myalgia 9 (15.5)
Back pain 8 (13.8)
Osteoarthritis 5 (8.6)
Pain in extremity 5 (8.6)
Tendonitis 3 (5.2)
Neck pain 3 (5.2)
General disorders and
administration site
conditions
Injection-site bruising 11 (19.0)
Injection site hemorrhage 7 (12.1)
Fatigue 5 (8.6)
Injection-site pain 5 (8.6)
Injection-site mass 3 (5.2)
Injection-site discoloration† 2 (3.4)
Injection-site erythema† 2 (3.4)
Injection-site swelling† 2 (3.4)
Injection-site induration† 1 (1.7)
Injection-site pruritus† 1 (1.7)
Injection-site urticaria† 1 (1.7)
Injury, poisoning and
procedural complications
Ligament sprain 5 (8.6)
Procedural pain 3 (5.2)
Safety events of interest§
Injection site reactions 21 (36.2)
Allergic events 6 (10.3)
Neurological events 5 (8.6)
Hypoaesthesia 2 (3.4)
Paraesthesia 2 (3.4)
Neuralgia 1 (1.7)
Neurocognitive eventsǁ 3 (5.2)
Disturbance in attention 2 (3.4)
Table 2 (continued)
TEAEs occurring in ≥5% of patients†
Amnesia 1 (1.7)
Memory impairment 1 (1.7)
MedDRA, Medical Dictionary for Regulatory Activities.
TEAE, treatment-emergent adverse event.
⁎ Safety analyses are reported for the duration of the study, with all patients who have
treatment ongoing having completed to at least 156 weeks (3 years) of open-label
therapy.
† Although reported by b5%, injection site reactions are of special interest given that
alirocumab is an injectable medication and these events are reported accordingly.
‡ MedDRA.
§ Categories based on standardized MedDRA queries.
ǁ Although three patients reported neurocognitive events, one patient reported two dif-
ferent events coming under this category.
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gle low-titer assay response at the last available assessment. No pattern
was observed in relation to positive ADA assay responses in these
patients and either incidence of TEAEs or reductions in LDL-C.
3.3. Lipids and lipoproteins
LDL-C was reduced from a mean (SD) baseline level of 150.7 (40.4)
mg/dL [3.9 (1.1) mmol/L] to 54.5 (40.5) mg/dL [1.4 (1.0) mmol/L]
at Week 24, an absolute reduction of 98.9 (37.9) mg/dL [2.6
(1.0) mmol/L] and a mean percentage reduction of 65.4 (21.1)%
(Fig. 2; Table 4). LDL-C reductions were sustained from Weeks 4
through 148 (P b 0.05 versus baseline at each time point; Fig. 2). At
Week 148, the mean achieved LDL-C level was 65.9 (35.5) mg/dL
[1.7 (0.9) mmol/L] (Fig. 2A), a mean (SD) percentage reduction of
56.0 (23.8)% from baseline (Table 4).
AtWeek 24, 51 of 55 patients (92.7%)whowere receiving treatment
achieved pre-deﬁned treatment goals of LDL-C b 70mg/dL (1.8mmol/L)
or b100 mg/dL (2.6 mmol/L) depending on risk. At Week 148, 78.4%
achieved their pre-deﬁned LDL-C goal (Fig. 2A).
At Week 24, the mean level of apo B fell by 50.9%, non-HDL-C by
55.7%, and median level of Lp(a) by 22.5%, versus baseline (P b 0.0001),
with reductions sustained fromWeek 4 onwards (Table 4; absolute levels
over time in Fig. 3A–C). At Week 24, HDL-C and apo A1 levels were in-
creased by 6.2% and 4.9%, respectively, versus baseline (both P b 0.05;Table 3
Laboratory parameters of interest.
Changes in laboratory parameters, n (%) All patients
(n = 58)
Albumin ≤25 g/L 0
Creatine kinase N3× ULN and ≤10× ULN 6 (10.3)
Creatine kinase N10× ULN 0
High sensitivity C-reactive protein N2× ULN
or N10 mg/L (if ULN not provided)
17 (29.3)
Alanine aminotransferase N3× ULN and ≤5 ULN 0
Alanine aminotransferase N5× and ≤10× ULN 1 (1.7)
Aspartate aminotransferase N3× ULN and ≤5 ULN 0
Aspartate aminotransferase N5× and ≤10× ULN 1 (1.7)
Bilirubin N1.5× ULN 6 (10.3)
Bilirubin N2× ULN 3 (5.2)
Bilirubin N2× ULN and alanine aminotransferase N3× ULN 0
Glycemic parameters
HbA1C, baseline, mean (SD), % 5.8 (0.4)
HbA1C, change from baseline at Week 148, mean (SD), % 0.1 (0.3)
Glucose, baseline, mean (SD), mmol/L [mg/dL] 5.6 (0.6) [100.0 (10.8)]
Glucose, change from baseline at Week 148, mean (SD),
mmol/L [mg/dL]
0.2 (0.8) [3.6 (14.3)]
Glucose ≤3.9 mmol/L [70.3 mg/dL] and bLLN, n 0
Glucose ≥11.1 mmol/L [200 mg/dL] (unfasted),
≥7.0 mmol/L [126 mg/dL] (fasted), n (%)
10 (17.2)
HbA1c, glycated hemoglobin LLN, lower limit of normal;
ULN, upper limit of normal.
Table 4
Percentage reductions from baseline in lipid efﬁcacy parameters at Week 24 (primary
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by 13.9% at Week 24 (Table 4; levels over time in Fig. 3E).analysis) and Week 148 (latest available efﬁcacy assessment for all patients continuing
to receive treatment).
Alirocumab 150 mg Q2W (N = 58)
Percentage reduction
from baseline†
Week 24 (n = 55) Week 148 (n = 51)
LDL-C −65.4 (21.1)⁎⁎ −56.0 (23.8)⁎⁎
Absolute levels,
mg/dL [mmol/L]
54.5 (40.5)
[1.4 (1.0)]
65.9 (35.5)
[1.7 (0.9)]
Apo B −50.9 (18.4)⁎⁎ −46.1 (20.6)⁎⁎
Non-HDL-C −55.7 (21.0)⁎⁎ −48.7 (23.3)⁎⁎
Lp(a) −22.5 (−50.0:−7.9)⁎⁎ −25.6 (−42.5:−8.1)⁎⁎
Triglycerides −13.9 (−29.5: 15.4) −15.1 (−33.3: 6.8)
HDL-C 6.2 (15.9)⁎ 3.6 (17.7)
Apo A1 4.9 (11.2)⁎ 5.6 (13.0)⁎⁎
Apo, apolipoprotein;HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipo-
protein cholesterol; Lp(a), lipoprotein (a); Q2W, every 2 weeks.
† Values aremean (SD) except for Lp(a) and triglycerides, forwhichmedian (interquartile
range) are shown.
⁎ P b 0.05
⁎⁎ P b 0.0001 vs. baseline.4. Discussion
Patients in this study had HeFH and a mean baseline LDL-C level of
151 mg/dL (3.9 mmol/L) despite treatment with high-dose statin (and
ezetimibe use in 72% of patients). These patients were therefore in
need of further LDL-C reduction. Addition of open-label alirocumab
150 mg Q2W to the patient's existing LLT resulted in a sustained mean
LDL-C reduction of ~60% from baseline over the course of the study.
The percentage reduction in LDL-C from baseline to Week 148 (56%)
was somewhat lower than that seen at Week 24 (65%). This could be
due to several reasons, including patient drop-outs, adjustment of
alirocumab dosing regimen from Q2W to Q4W in some patients, and
adjustment of background lipid medication in some patients. However,
atWeek 148, themean LDL-Cwas 65.9mg/dL [1.7mmol/L], an absolute
mean (SD) reduction from baseline of 85.6 (40.5) mg/dL [2.2 (1.0)
mmol/L], and ~80% of patients had achieved their LDL-C goal. These re-
ductions are comparable with those observed in Phase 3 double-blind
trials of alirocumab in patients with HeFH [7]. Alirocumab also resulted
in substantial sustained decreases in Lp(a) over 148 weeks, similar to
reductions observed previously [9,10]. Elevated Lp(a) is an indepen-
dent risk factor for CVD [10]; however, the clinical implications of
reducing Lp(a) and the precise mechanism of alirocumab effect on
Lp(a) have yet to be fully determined.Fig. 2. Absolute LDL-C levels over time and achievement of (A) risk-baOpen-label treatment over 3 years with alirocumab 150 mg Q2W
had a safety proﬁle comparable with that seen in a pooled analysis of
14 randomized, double-blind, Phase 2 and 3 clinical trials of alirocumab
including over 5000 patients [11]. The most common type of TEAEs in
this open-label study were injection site reactions, which were mostly
mild and did not result in treatment discontinuation. Alirocumabsed LDL-C goals and (B) LDL-C percentage change from baseline.
Fig. 3. Levels of other lipids and lipoproteins over time: (A) apo B, (B) non-HDL-C, (C) Lp(a), (D)HDL-C, and (E) triglycerides. Values shown on the charts are rounded to one decimal place.
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compared with controls in double-blind trials [11]. Neurological and
neurocognitive events reported in this open-label study were not con-
sidered to be related to alirocumab treatment. In double-blind trials,
no increase in neurological or neurocognitive events was associated
with alirocumab [11]. Treatment with statins has been associated with
an increased incidence of diabetes mellitus [12]. In the present study,
alirocumab did not meaningfully impact glycemic parameters (HbA1C
and glucose), in agreement with results reported from across the
alirocumab clinical trial program [12]. No pattern was observed in
relation to the ADA responses (n = 3) and either incidence of TEAEs
or reductions in LDL-C. No speciﬁc safety concerns were identiﬁed in
patients who reached LDL-C values b25 mg/dL (b0.65 mmol/L) or
b15 mg/dL (b0.39 mmol/L); similarly, no safety signals were identiﬁed
in patients with LDL-C b 25mg/dL in the ODYSSEY LONG TERM trial [9].
Patients with HeFH typically have LDL-C levels of 200–500 mg/dL
(5.2–12.9 mmol/L) prior to treatment, far above the optimal level of
b100 mg/dL (b2.6 mmol/L) for adults (or b70 mg/dL [1.8 mmol/L] in
thosewith pre-existing CVdisease). Although there had been continued
improvement in LDL-C levels in patients with HeFH since the advent of
statins, development of more potent statins, and addition of ezetimibe,
the majority of these patients were still not achieving sufﬁcientreduction in LDL-C levels (~80% were not at goal in recent studies [5,
6]). There has therefore been great interest in using PCSK9 inhibitors
for treatment of HeFH. However, understanding the long-term safety
and efﬁcacy of PCSK9 inhibitors is important for this lifelong condition.
Data from this study represent the longest exposure to date with
alirocumab in patients with HeFH.
Limitations of this study include the potential bias introduced
by having an open-label treatment. Over a 3-year follow-up period,
a higher overall rate of AEsmay be expected; however, the lack of a com-
parative control and relatively low patient numbers limit the
interpretation of results. Studies with a longer duration of exposure to
alirocumab are required to provide further reassurance about incidence
of neurological and neurocognitive events. The ongoing ODYSSEY
OUTCOMES trial (involving over 18,000 patients) is evaluating the effect
of alirocumab on CV events and will also provide further information on
long-term safety [13].
5. Conclusion
In patients with HeFH who were receiving stable background statin
with or without ezetimibe, treatment with open-label alirocumab
150mgQ2Wfor 3 yearswaswell-tolerated,with no evidence of speciﬁc
760 R. Dufour et al. / International Journal of Cardiology 228 (2017) 754–760safety signals including in those patients with LDL-C b 25 mg/dL.
Alirocumab treatment resulted in signiﬁcant, sustained reductions in
LDL-C of approximately 60% and allowed achievement of LDL-C goals
previously unobtainable in these patients with statins and other
current lipid-lowering therapies. Substantial reductions in Lp(a), an
independent cardiovascular risk factor, were also observed.
Supplementary data to this article can be found online at doi:10.
1016/j.ijcard.2016.11.046.
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